Deutsche Bank AG Invests $2.49 Million in REGENXBIO Inc. $RGNX

Key Points

• Deutsche Bank acquired 207,835 REGENXBIO shares during the second quarter, valued at approximately $2.49 million and representing a 0.40% stake. Institutional investors collectively own 88.08% of the company.
• Analyst sentiment is generally positive, with nine Buy ratings, three Holds and one Sell; the stock has a consensus rating of “Moderate Buy” and an average price target of $23.27.
• REGENXBIO reported quarterly EPS of $0.43, beating the $0.08 consensus estimate, while revenue of $108.02 million exceeded expectations. Despite the earnings beat, the company remains unprofitable, with a negative net margin of 112.58%.

Deutsche Bank AG acquired a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 207,835 shares of the biotechnology company's stock, valued at approximately $2,490,000. Deutsche Bank AG owned 0.40% of REGENXBIO at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Versant Capital Management Inc lifted its position in shares of REGENXBIO by 60.4% during the 2nd quarter. Versant Capital Management Inc now owns 2,741 shares of the biotechnology company's stock valued at $33,000 after acquiring an additional 1,032 shares during the period. Captrust Financial Advisors increased its stake in REGENXBIO by 13.2% in the 4th quarter. Captrust Financial Advisors now owns 15,228 shares of the biotechnology company's stock valued at $219,000 after purchasing an additional 1,781 shares in the last quarter. Diversified Trust Co raised its holdings in REGENXBIO by 15.9% during the first quarter. Diversified Trust Co now owns 15,499 shares of the biotechnology company's stock worth $130,000 after purchasing an additional 2,121 shares during the last quarter. Intech Investment Management LLC raised its holdings in REGENXBIO by 12.2% during the fourth quarter. Intech Investment Management LLC now owns 21,367 shares of the biotechnology company's stock worth $308,000 after purchasing an additional 2,327 shares during the last quarter. Finally, Focus Partners Advisor Solutions LLC boosted its position in REGENXBIO by 24.0% during the fourth quarter. Focus Partners Advisor Solutions LLC now owns 12,676 shares of the biotechnology company's stock worth $183,000 after purchasing an additional 2,455 shares in the last quarter. Institutional investors and hedge funds own 88.08% of the company's stock.

Wall Street Analyst Weigh In

RGNX has been the topic of a number of research reports. Morgan Stanley reissued an "overweight" rating and issued a $18.00 price objective on shares of REGENXBIO in a research note on Friday, August 7th. Zacks Research upgraded REGENXBIO from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 12th. Weiss Ratings reiterated a "sell (e+)" rating on shares of REGENXBIO in a report on Monday, June 8th. Robert W. Baird dropped their price target on REGENXBIO from $32.00 to $29.00 and set an "outperform" rating for the company in a research report on Tuesday. Finally, Wall Street Zen raised REGENXBIO from a "strong sell" rating to a "hold" rating in a report on Saturday, August 8th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $23.27.

REGENXBIO Price Performance

NASDAQ RGNX opened at $9.37 on Friday. The company has a market cap of $618.51 million, a P/E ratio of -2.47 and a beta of 0.94. REGENXBIO Inc. has a 12 month low of $5.45 and a 12 month high of $16.19. The company has a 50-day moving average of $11.03 and a 200-day moving average of $9.20.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.08 by $0.35. The firm had revenue of $108.02 million during the quarter, compared to analyst estimates of $97.63 million. REGENXBIO had a negative net margin of 112.58% and a negative return on equity of 220.07%. As a group, equities research analysts anticipate that REGENXBIO Inc. will post -3.91 EPS for the current year.

Insider Transactions at REGENXBIO

In other REGENXBIO news, insider Steve Pakola sold 2,161 shares of the company's stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $13.64, for a total transaction of $29,476.04. Following the completion of the sale, the insider directly owned 213,009 shares in the company, valued at $2,905,442.76. This represents a 1.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders sold a total of 58,494 shares of company stock worth $718,232 over the last ninety days. 14.22% of the stock is currently owned by insiders.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO's pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source